Drug Type Bispecific antibody |
Synonyms CKD 702, CKD702 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal junction adenocarcinoma | Phase 2 | KR | 01 Dec 2022 | |
Neoplasms | Phase 1 | KR | 30 Jan 2022 |
NCT04667975 (ESMO2022) Manual | Phase 1 | metastatic non-small cell lung cancer EGFR Exon 19 Deletion | EGFR L858R | Met Exon 14 Skipping ... View more | 24 | (All pts) | nybzrymlos(yuaeheupue) = hjrnpuwxne nrqtleujhg (tuijkfjqas ) View more | Positive | 10 Sep 2022 |
(Met ex14 skipping) | trqkxucnxm(cikmvefjwg) = bcqtquxgcj jjhqiuuubx (cxuxjbnfzy ) View more |